Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Valerio, Gabriela, Martínez-Lozano, Mar, Bassani, Nicklas, Vidal, August, Ochoa-de-Olza, María, Suárez, Cristina, García-del-Muro, Xavier, Carles, Joan, Viñals, Francesc, Graupera, Mariona, Indraccolo, Stefano, Casanovas, Oriol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870515/
https://www.ncbi.nlm.nih.gov/pubmed/27134180
http://dx.doi.org/10.1016/j.celrep.2016.04.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870515/
https://www.ncbi.nlm.nih.gov/pubmed/27134180
http://dx.doi.org/10.1016/j.celrep.2016.04.015

Ejemplares similares